25 protocols found



Protocol No. Title Status
HO07403 A Longitudinal Study to Evaluate Changes in Cellular Protein Expression and Activation in Bone Marrow Tumor Cells and Stromal Cells from Patients with Multiple Myeloma Open
UW17157 A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma Open
UW18105 A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Open
UW19023 A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study GSK2857916 as monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) -- DREAMM 5 Open
UW16139 A Pilot Study to Evaluate the Therapeutic Response of Tumor Cells Co-cultured with Non-tumor Cells from Patients with Multiple Myeloma ex vivo Open
BMTCTN1705 A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW16144 An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) Open
BMTCTN1704 Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplant (CHARM) Open
EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Open
UW15106 Genomic Analysis of Long-Term Survivors with Metastatic Cancer Open
ADVL1823 Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
NCICOVID NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621I NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes Open
S1803 Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) Open
UW19082 Symptom Burden, Co-Occurrence, and Trajectories in Children with Advanced Cancer Open
UW19038 Symptom Cluster Experience of Cancer Patient-Caregiver Dyads Open
UW18073 Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation Open
UW13056 Women's Integrative Sexual Health (WISH) Program Research Database Open